Overview

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Unity Biotechnology, Inc.
Treatments:
Aflibercept